Navigation Links
Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
Date:11/24/2008

PRINCETON, N.J., Nov. 24 /PRNewswire-FirstCall/ --Medarex, Inc. (Nasdaq: MEDX) today announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer. Studies suggest that the PD-1 signaling pathway may play an important role in tumor evasion and escape from host immune responses and may also promote the persistence of certain chronic viral infections.

The Phase 1b clinical trial is designed to primarily evaluate the safety and tolerability of repeated dosing of MDX-1106 in adult patients with solid tumors and will also provide a preliminary assessment of the anti-tumor activity of multiple doses of MDX-1106 (1, 3 or 10 mg/kg) in these patients. The tumors to be studied include malignant melanoma, renal cell cancer, castrate-resistant prostate cancer and non-small cell lung carcinoma. This open label study is expected to enroll up to 76 patients and will be conducted in multiple sites in the United States.

"We believe that anti-PD-1 antibodies could represent the next stage in immunotherapy with a promising mechanism of action and potential for marked synergy with anti-CTLA4 antibodies," said Geoffrey M. Nichol, MBChB, Senior Vice President of Product Development at Medarex. "Preliminary results from our single-dose Phase 1 study demonstrated an acceptable safety profile and initial evidence of anti-tumor activity in cancer. We look forward to the further development of this novel immunotherapy in cancer and, in a separate clinical trial, hepatitis C."

In May 2005, Ono entered into a collaboration agreement with Medarex to research and develop a fully human anti-PD-1 antibody for the treatment of cancer. The two companies plan to share the costs and responsibilities of researc
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
9. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
10. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
11. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Mindray (NYSE: MR)announced its new generation DC-70 ... has been showcased for the first time at ISUOG ... and is scheduled for availability in the U.S. market ... most efficient workhorse in the mid-range segment, the DC-70 ... optimized user experience including a gesture-sensitive touch screen, delivering ...
(Date:9/16/2014)... Sept. 16, 2014 This report analyzes the worldwide ... the following Product Segments: SPECT Systems (Includes SPECT and SPECT/CT ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... and forecasts are provided for the period 2013 through 2020. ...
(Date:9/16/2014)... Tenn. , Sept. 16, 2014 A ... investigators has found the chemotherapy dose threshold below ... normal sperm production. The study appears in September 17 ... By clarifying which patients are at highest risk ... findings to eventually increase use of pre-treatment fertility preservation ...
Breaking Medicine Technology:Quality Exams at Your Fingertips 2Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 26Improved risk identification will aid fertility preservation in young male cancer patients 2Improved risk identification will aid fertility preservation in young male cancer patients 3Improved risk identification will aid fertility preservation in young male cancer patients 4
... (Nasdaq: VPHM ) today announced that its ... cytomegalovirus (CMV) disease in liver transplant patients has been ... being moved to the current standard of care. The ... Phase 3 study of maribavir in stem cell transplant ...
... children for acute osteomyelitis--a bacterial bone infection--an early changeover ... just as effective as continuing the IV therapy, according ... more convenient for children and families, and avoid a ... from using central catheters, such as infections or breaks ...
Cached Medicine Technology:ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients 2ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients 3ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients 4Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 2Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 3
(Date:9/17/2014)... Angeldress.co.uk is a popular ... occasion outfits for worldwide clients. According to Leo, the ... opening the first flagship retail store. Moreover, it is ... company has unveiled its new range of amazing wedding ... its new products are offered at greatly discounted prices, ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 There’s ... interruptions, giving girls of all ages an all-natural ... company founded by women, for women, announces the ... (http://GirlU.com) to relieve the symptoms commonly ... and irritability. , As a lifelong health ...
(Date:9/17/2014)... San Diego, CA (PRWEB) September 17, 2014 ... Dermatology in San Diego, Dr. William Groff, an expert on ... of treating it. Pearly penile papules , or PPP, ... twenties and thirties, although other men may be affected as ... head of the penis. , “While PPP is not ...
(Date:9/17/2014)... 17, 2014 A raucous childhood in ... together to form author Nancy Chovancek’s laughter-filled new book, ... a collection of short stories that prove the best ... With a positive message of empowerment and resilience, everyone ... a proven author with two books under her belt ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 ... District (DHCHD) has implemented its CollaborNet™ Health ... exchange of patients’ health information between Coon Memorial ... Texas, and physicians in the community. , ... application to enable electronic referrals by physicians to ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Is Planning To Open Its First Retail Store And Offering Big Savings On Amazing Wedding Dresses 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 3Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 4Health News:New Video Depicts Best Treatment for PPP 2Health News:New Video Depicts Best Treatment for PPP 3Health News:Dallam-Hartley Counties Hospital District Deploys Holon's Health Information Exchange (HIE) Solution to Facilitate Improved Patient Care 2Health News:Dallam-Hartley Counties Hospital District Deploys Holon's Health Information Exchange (HIE) Solution to Facilitate Improved Patient Care 3
... 2007 A review published in Dermatologic Therapy reveals that ... the same way as women but require higher doses of ... become a growing interest in cosmetic procedures by men. Although ... male patients who seek treatment is slowly increasing. , ...
... ceremony of, facility being built to serve the western Palm ... ... Dec. 28 The Health Care District,of Palm Beach County Board ... Board of Directors recently,dedicated the 50 acres of land on which ...
... plus fluticasone therapy led to better health, large trial ... People suffering with chronic obstructive pulmonary disease (COPD) may ... risk of death within two years as well and ... new research suggests. , The conclusion is drawn ...
... Dec. 28 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX,- ... for Drug Delivery,Platforms, announce that in order to ... directors, consultants and employees plan to,exercise stock options ... Lee, President and CEO, will cancel 6,000,000 options,granted ...
... NYSE Agrees to a Trading Extension of KV,s Securities until February ... ... 2008, ST. LOUIS, Dec. 28 KV Pharmaceutical Company,(NYSE: ... markets technology differentiated,branded and generic/non-branded prescription pharmaceutical products,announced today that NYSE ...
... of the Philadelphia Ronald McDonald House, will ... Ceremony on, Thursday, January 3rd; House ... PHILADELPHIA, Dec. 28 The 27,000-square-foot,three-story "Philadelphia Ronald ... its doors on Monday, January 7, 2008 - ...
Cached Medicine News:Health News:Work Begins on New Regional Hospital Medical Campus 2Health News:Work Begins on New Regional Hospital Medical Campus 3Health News:Work Begins on New Regional Hospital Medical Campus 4Health News:Drug Combo Halves Death Risk for Severe COPD Patients 2Health News:AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 3Health News:'Philadelphia Ronald McDonald House(R) at Front & Erie' Celebrates Grand Opening 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: